

Recent Advances in the Treatment of Lung, Head/Neck Cancers

Friday, April 24, 2009, Hummelstown, PA
7:30 am - 2:25 pm

Hilton Garden Inn Hershey, 550 East Main Street, Hummelstown, PA 17036
Phone: 717-566-9292

Program Directors

Chandra P. Belani, MD

Miriam Beckner Distinguished Professor of Medicine
Penn State Milton S. Hershey Medical Center
Penn State College of Medicine
Deputy Director, Penn State Cancer Institute, Hershey, PA

Statement of Need/Program Overview

This program is intended to facilitate interaction among oncologists, nurses, pharmacist, physician assistants, and nurse practitioners interested in the development of novel therapeutics for treatment of lung, head/neck cancer. This symposium will present data of most promising emerging agents currently in development for the treatment of lung, head/neck cancers. There will be in-depth discussion of targeted therapies for lung, head/neck cancers.

Target Audience:

This symposium is directed primarily to medical oncologists, radiation oncologists, pharmacists, and registered oncology nurses interested in new developments for treatment of lung cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.

Physician Continuing Medical Education

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Lung Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Postgraduate Institute for Medicine designates this educational activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Purpose: The purpose of this educational meeting is to assist healthcare providers develop appropriate treatment strategies that minimize side effects and optimize outcomes in patients with lung cancer.

Credit Designation

This educational activity for 4.7 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statements

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks (if applicable).

Pharmacist Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates each session of this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Session I Universal Program Number 809-999-09-044-L01-P; Session II Universal Program Number 809-999-09-045-L01-P ; Session III Universal Program Number 809-999-09-046-L01-P)

Jointly sponsored by International Lung Cancer Network and Postgraduate Institute for Medicine

First Name _____ Middle Initial _____ Last Name _____

Physician Pa-C Fellow NP PhD Pharmacist Industry Nurse Other

Specialty _____

Mailing Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____ E-Mail _____

Registration Fee

Registration fee partially covers continental breakfast, lunch and syllabus book

Physicians \$50.00 Nurses, Pharmacists, others \$30.00
 Fellows No Registration Fee *Industry \$325.00

*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: MC Visa Discover Amex Check

Credit Card Number _____ Expiration Date _____ Security code (AmEx on front) _____

Name and address as it appears on Credit Card _____

Signature _____

Register online at www.Internationalcancernetwork.com

Please make checks payable to International Lung Cancer Network. Mail checks to PO Box 116609, Carrollton, TX 75011-6609

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or

E-mail: knaidu@internationalcancernetwork.com

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.

Fax registration to:
443-267-0016

Mail registration to:
PO Box 116609
Carrollton, TX 75011-6609

Recent Advances in the Treatment of Lung, Head/Neck Cancers

Friday, April 24, 2009, Hummelstown, PA

7:30 am - 2:25 pm

7:30 am BREAKFAST

7:30 am Registration and Breakfast

8:25 am Welcome and Introductions

Chandra P. Belani, MD

Targeted Therapies: Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Targets

Chair: Chandra P. Belani, MD

8:30 am Advanced Non-Small-Cell Lung Cancer: Management in the Bevacizumab Era

Chandra P. Belani, MD

8:55 am Other Vascular Endothelial Growth Factor Targeting Agents Including Sutent, Sorafenib and Trial Designs

George Simon, MD

9:20 am Combined Modality Therapy of Lung, Head/Neck Cancers

Walter Curran, MD

9:45 am Panel Discussion

10:05 am BREAK

Targeted Agents: Emerging Novel Agents

Chair: Suresh Ramalingam, MD

10:15 am Optimizing the Use of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Suresh Ramalingam, MD

10:40 am Epidermal Growth Factor Receptor Monoclonal Antibodies with and without Radiation Therapy for Non-Small-Cell Lung Cancer

Roy Herbst, MD

11:05 am Recurrent Non-Small-Cell Lung Cancer: Second Line Therapy - Standard of Care and Emerging Agents

Suresh Ramalingam, MD

11:30 am Panel Discussion

11:50 am LUNCH

Novel Therapeutic Agents in the Horizon

Chair: Chandra P. Belani, MD

12:50 pm New Systemic Therapies for Head/Neck Cancers

Corey Langer, MD

1:15 pm Proteasome Inhibitors, HDAC Inhibitors and Novel Taxanes in Treatment of Lung Cancer

Chandra P. Belani, MD

1:40 pm Emerging Novel Agents and Vaccines of Interest for Lung Cancer

Fadlo Khuri, MD

2:05 pm Panel discussion

2:25pm CLOSING REMARKS & ADJOURN

Chandra P. Belani, MD

Educational Grants:

This program is supported by educational grants from:

Bristol-Myers Squibb/ImClone Systems
Genentech BioOncology

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.